Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation
(allo-HSCT) could be a valuable treatment choice for TP53+ myeloid tumors, such as acute
myeloid leukemia and myelodysplastic syndrome. Unfortunately, some patients relapsed after
allo-HSCT. In this prospective randomized controlled study, the safety and efficacy of
Decitabine + BUCY and BUCY myeloablative conditioning regimens in TP53+ myeloid tumors
undergoing allo-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital